Merged with Nano Precision Medical to form Vivani Medical (NASDAQ:VANI) in Sep 2022
EYES - Second Sight Medical Products, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
Sylmar,
United States
Type: Equity
EYES price evolution
EYES
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $56.38 | $59.6 | $69.59 | $72.03 |
| Short term investments | ||||
| Net receivables | $0.2 | $0.3 | ||
| Inventory | ||||
| Total current assets | $57.39 | $60.22 | $70.51 | $73.22 |
| Long term investments | $8 | $8 | ||
| Property, plant & equipment | $0.24 | $0.3 | $0.34 | $0.39 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $8.26 | $8.32 | $0.37 | $0.41 |
| Total investments | $8 | $8 | ||
| Total assets | $65.65 | $68.54 | $70.88 | $73.63 |
| Current liabilities | ||||
| Accounts payable | $0.97 | $0.74 | $0.52 | $0.76 |
| Deferred revenue | $0.34 | |||
| Short long term debt | $0.15 | $0.2 | $0.18 | $0.18 |
| Total current liabilities | $2.59 | $2.38 | $2.46 | $3.92 |
| Long term debt | $0.05 | $0.1 | ||
| Total noncurrent liabilities | $0.05 | $0.1 | ||
| Total debt | $0.15 | $0.2 | $0.24 | $0.28 |
| Total liabilities | $2.59 | $2.38 | $2.51 | $4.02 |
| Shareholders' equity | ||||
| Retained earnings | -$333.87 | -$330.8 | -$328.58 | -$327.3 |
| Other shareholder equity | -$0.42 | -$0.39 | -$0.38 | -$0.4 |
| Total shareholder equity | $63.06 | $66.15 | $68.36 | $69.61 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $69.59 | $3.18 | $11.33 | $4.47 |
| Short term investments | ||||
| Net receivables | $0.3 | $0.46 | $0.5 | |
| Inventory | $1.03 | $3.25 | ||
| Total current assets | $70.51 | $4.27 | $13.11 | $9.62 |
| Long term investments | ||||
| Property, plant & equipment | $0.34 | $0.17 | $3.46 | $1.02 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.37 | $0.19 | $3.49 | $1.06 |
| Total investments | ||||
| Total assets | $70.88 | $4.46 | $16.6 | $10.68 |
| Current liabilities | ||||
| Accounts payable | $0.52 | $0.49 | $1.09 | $1.3 |
| Deferred revenue | $0.34 | $0.34 | $0.17 | |
| Short long term debt | $0.18 | $2.2 | $0.24 | |
| Total current liabilities | $2.46 | $5.13 | $6.96 | $7.6 |
| Long term debt | $0.05 | $2.37 | ||
| Total noncurrent liabilities | $0.05 | $2.37 | ||
| Total debt | $0.24 | $2.2 | $2.6 | |
| Total liabilities | $2.51 | $5.13 | $9.32 | $7.6 |
| Shareholders' equity | ||||
| Retained earnings | -$328.58 | -$319.66 | -$304.78 | -$269.47 |
| Other shareholder equity | -$0.38 | -$0.45 | -$0.56 | -$0.57 |
| Total shareholder equity | $68.36 | -$0.67 | $7.28 | $3.08 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | -$0.13 | |||
| Gross Profit | $0.13 | |||
| Operating activities | ||||
| Research & development | $0.84 | $0.65 | $0.64 | $0.7 |
| Selling, general & administrative | $2.13 | $1.47 | $0.97 | $1.53 |
| Total operating expenses | $3.13 | $2.22 | $1.42 | $2.5 |
| Operating income | -$3.13 | -$2.22 | -$1.29 | -$2.5 |
| Income from continuing operations | ||||
| EBIT | -$3.08 | -$2.21 | -$1.28 | -$2.5 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$3.08 | -$2.21 | -$1.28 | -$2.5 |
| Income (for common shares) | -$3.08 | -$2.21 | -$1.28 | -$2.5 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.38 | $6.9 | ||
| Cost of revenue | -$0.13 | -$0.5 | $2.15 | $4.89 |
| Gross Profit | $0.13 | $0.5 | $1.23 | $2.01 |
| Operating activities | ||||
| Research & development | $2.37 | $4.84 | $13.14 | $10.01 |
| Selling, general & administrative | $6.32 | $6.64 | $15.33 | $22.03 |
| Total operating expenses | $9.06 | $15.4 | $35.18 | $37.19 |
| Operating income | -$8.93 | -$14.9 | -$33.95 | -$35.18 |
| Income from continuing operations | ||||
| EBIT | -$8.92 | -$14.88 | -$33.59 | -$35.09 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$8.92 | -$14.88 | -$33.59 | -$35.09 |
| Income (for common shares) | -$8.92 | -$14.88 | -$33.59 | -$35.09 |
| (in millions $) | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 |
|---|---|---|---|---|
| Net income | -$3.08 | -$2.21 | -$1.28 | -$2.5 |
| Operating activities | ||||
| Depreciation | $0.01 | $0.02 | $0.01 | $0.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.01 | $0.01 | $0.02 | $0.02 |
| Total cash flows from operations | -$3.22 | -$1.98 | -$2.42 | -$1.8 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.01 | ||
| Investments | -$8 | |||
| Total cash flows from investing | -$8.02 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0 | |||
| Effect of exchange rate | -$0 | $0 | -$0.02 | |
| Change in cash and equivalents | -$3.22 | -$9.99 | -$2.44 | -$1.82 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$8.92 | -$14.88 | -$33.59 | -$35.09 |
| Operating activities | ||||
| Depreciation | $0.08 | $0.17 | $0.41 | $0.43 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.07 | $0.42 | $2.92 | $3.7 |
| Total cash flows from operations | -$9.19 | -$16.82 | -$27.63 | -$29.81 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.33 | -$0.49 | -$0.16 |
| Investments | ||||
| Total cash flows from investing | -$0.01 | $0.07 | -$0.49 | -$0.16 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $77.81 | $6.4 | $34.99 | $26.6 |
| Net borrowings | -$2.2 | $2.2 | ||
| Total cash flows from financing | $75.62 | $8.6 | $34.99 | $26.6 |
| Effect of exchange rate | $0 | $0.01 | -$0.01 | $0 |
| Change in cash and equivalents | $66.42 | -$8.15 | $6.86 | -$3.37 |
News
|
Prominent ophthalmologist will guide Turn Bio's search for therapies to cure eye diseases
KCRG-TV9 Cedar Rapids
22 Aug 2022
|
|
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday By Benzinga
Investing.com
22 Aug 2022
|
|
Sight Sciences Grows Portfolio Amid Reimbursement Pressure (NASDAQ:SGHT)
Seeking Alpha
19 Aug 2022
|
|
Sight Sciences, Inc. (SGHT) Q2 2022 Earnings Call Transcript
Motley Fool
12 Aug 2022
|
|
Doximity (DOCS) to Report Q1 Earnings: What's in the Offing?
Zacks via Yahoo Finance
3 Aug 2022
|
|
Council Post: Advancing Artificial Intelligence And Creating The Technology Of The Future
Forbes
3 Aug 2022
|
|
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
Zacks via Yahoo Finance
2 Aug 2022
|
|
Univec, Inc. (OTCMKTS:UNVC) Sees Large Drop in Short Interest
ETF DAILY NEWS
30 Jul 2022
|
|
Public records for the week of May 16
The Virginian-Pilot
16 May 2022
|
|
Atlanta startups see drop in funding during April
The Business Journals
5 May 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 13.14M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$9.01M |
| EBIT | -$9.07M |
| Net Income | -$9.07M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 4.83 |
| Cash/Share | 4.29 |
| EPS | -$0.69 |
|---|---|
| ROA | -13.02% |
| ROE | -13.58% |
| Debt/Equity | 0.04 |
|---|---|
| Net debt/EBITDA | 5.97 |
| Current ratio | 22.15 |
| Quick ratio | 22.15 |